Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STT-5058 in subjects with elevated triglyceride levels
NCT04419688Phase 1Terminated
- Sponsor
- Staten Biotechnology
- Start
- May 2020
- Primary completion
- Dec 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hypertriglyceridemia comparing STT-5058 with Placebo (2 arms). Primary endpoint: Safety and tolerability at 10 weeks. Started May 2020; status: terminated.
02
Drugs
STT-5058
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT04419688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04419688.